Occulogix Inc (TLB.TO) 4.83 $TLB.TO
TearLab Corporation to Release Q2 2014 Financial Results on August 7, 2014
GlobeNewswire - Wed Jul 16, 4:30PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q2 2014 financial results after market closes on Thursday, August 7, 2014. TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. That call will be held at 4:30pm Eastern at 877-303-1593.
Manoj Venkiteshwar Joins TearLab as VP of Medical Affairs
GlobeNewswire - Mon Jul 14, 3:15PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
today announced the appointment of Manoj S. Venkiteshwar, PhD. to its senior management team in the newly created position of Vice President of Medical Affairs.
TearLab Announces Election of Directors
GlobeNewswire - Fri Jun 13, 3:02PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" announced that all of the nominees listed in the management information circular for the annual meeting of shareholders held on Wednesday, June 11, 2014 were elected as directors of the Company.
TearLab to Participate in the 11th Annual Craig-Hallum Institutional Investor Conference
GlobeNewswire - Wed May 21, 4:01PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" announced today that its Chief Executive Officer, Elias Vamvakas, will participate in the 11th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 28, 2014. The conference will be held at the Minneapolis Marriott City Center Hotel.
TearLab Closes Acquisition of AOA's OcuHub Technology Platform
GlobeNewswire - Fri Mar 14, 11:30AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" today announced the closing of the acquisition of the assets of the OcuHub business unit from AOAExcel, Inc., the for-profit subsidiary of the American Optometric Association ("AOA".
TearLab Corporation Reports 2013 Financial Results
GlobeNewswire - Thu Mar 13, 3:02PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" today reported its consolidated financial results for the quarter and the year ended December 31, 2013. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles.
TearLab to Participate in March Investor Conferences
GlobeNewswire - Tue Mar 04, 8:00AM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" announced today that the Company will participate in three investor conferences in March.
TearLab Corporation to Release Q4 and Full Year 2013 Financial Results on March 13, 2014
GlobeNewswire - Mon Mar 03, 3:30PM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q4 2013 and full year 2013 financial results after market closes on Thursday, March 13, 2014. TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. This call will be held at 4:30pm Eastern at 877-303-1593.
TearLab to Acquire AOA's OcuHub Technology Platform
GlobeNewswire - Tue Feb 18, 7:02AM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" today announced it has signed a non-binding term sheet to purchase the assets of the OcuHub business unit from AOAExcel, Inc., the for-profit subsidiary of the American Optometric Association ("AOA".
TearLab Announces Preliminary Fourth Quarter 2013 Revenue and Issues 2014 Revenue Guidance
GlobeNewswire - Mon Feb 03, 7:00AM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" today announced total revenue for the fourth quarter of 2013 is expected to be approximately $4.5 million, bringing expected full year 2013 revenues to approximately $14.7 million. These figures are preliminary and unaudited and final revenues may differ. The Company currently expects to report final 2013 financial results on March 13, 2014.
TearLab Reports on Launch of a New 1,000 Patient Multi-Center DED Prevalence Study in the UK
GlobeNewswire - Tue Dec 17, 7:00AM CST
In collaboration with the United Kingdom's National Health Service (NHS), four ophthalmologists are beginning a large 1,000 patient multi-center study to assess the overall prevalence of Dry Eye Disease ("DED".
TearLab to Participate in Craig-Hallum's 4th Annual Alpha Select Conference
GlobeNewswire - Thu Sep 19, 8:20AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" announced today that its Chief Executive Officer, Elias Vamvakas, will present an update on the Company's business at the 4th Annual Craig-Hallum Alpha Select Conference on Thursday, September 26, 2013 at 8:35 a.m. Eastern Time in New York City.
TearLab to Participate in the Canaccord Genuity 33rd Annual Growth Conference
GlobeNewswire - Wed Aug 07, 7:55AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company" announced today that its Chief Executive Officer, Elias Vamvakas, will present an update on the Company's business at the Canaccord Genuity 33rd Annual Growth Conference on Wednesday, August 14, 2013 at 11:00 a.m. Eastern Time. The conference will be held at the Intercontinental Boston Hotel in Boston, MA.
TearLab Corporation to Release Q2 2013 Financial Results on August 13, 2013
GlobeNewswire - Wed Jul 31, 7:00PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q2 2013 financial results after market closes on Tuesday, August 13, 2013.
TearLab Announces Exercise of Underwriters' Over-Allotment Option and Closing of $40.4 Million Public Offering of Common Stock
GlobeNewswire - Tue Jul 30, 10:40AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that it has closed the previously announced underwritten public offering of 2,990,000 shares of its common stock at a price to the public of $13.50 per share for gross proceeds of approximately $40.4 million. The shares include 390,000 shares of common stock sold pursuant to the over-allotment option granted by TearLab to the underwriters, which option was exercised in full. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by TearLab, will be approximately $37.5 million.
TearLab Corporation Prices $35.1 Million Public Offering of Common Stock
GlobeNewswire - Thu Jul 25, 8:00AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced the pricing of an underwritten public offering of 2,600,000 shares of its common stock at a price to the public of $13.50 per share for gross proceeds of $35.1 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by TearLab, will be approximately $32.6 million. TearLab has also granted the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover overallotments.
TearLab Corporation Announces Proposed Public Offering of Common Stock and Preliminary Second Quarter Financial and Operational Results
GlobeNewswire - Mon Jul 22, 6:00AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or "the Company" announced today its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company currently estimates the size of the offering at $30.0 million, with an estimated additional $4.5 million subject to the underwriters' over-allotment option described below. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. The proceeds of the offering will be used for commercialization of our products, research and development, working capital and other general corporate purposes.
Canaccord Genuity Updates Buy Recommendation on TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) - Video Posted on InvestmentPitch.com
Thomson Reuters ONE - Mon May 27, 9:30AM CDT
Vancouver, British Columbia, May 27, 2013 - Investment firm Canaccord Genuity has updated its buy recommendation on TearLab Corporation (NASDAQ:TEAR) (TSX:TLB). Analyst Jeffrey Frelick gives the company a buy rating and raised the one-year price target from US$10.00 to US$14.00, a 46% premium to the US$9.56 price the day the report was issued.
TearLab Corporation to Release Q2 2014 Financial Results on August 7, 2014
GlobeNewswire - Wed Jul 16, 4:30PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q2 2014 financial results after market closes on Thursday, August 7, 2014. TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. That call will be held at 4:30pm Eastern at 877-303-1593.
Manoj Venkiteshwar Joins TearLab as VP of Medical Affairs
GlobeNewswire - Mon Jul 14, 3:15PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
today announced the appointment of Manoj S. Venkiteshwar, PhD. to its senior management team in the newly created position of Vice President of Medical Affairs. TearLab Announces Election of Directors
GlobeNewswire - Fri Jun 13, 3:02PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
announced that all of the nominees listed in the management information circular for the annual meeting of shareholders held on Wednesday, June 11, 2014 were elected as directors of the Company. TearLab to Participate in the 11th Annual Craig-Hallum Institutional Investor Conference
GlobeNewswire - Wed May 21, 4:01PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
announced today that its Chief Executive Officer, Elias Vamvakas, will participate in the 11th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 28, 2014. The conference will be held at the Minneapolis Marriott City Center Hotel. TearLab Closes Acquisition of AOA's OcuHub Technology Platform
GlobeNewswire - Fri Mar 14, 11:30AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
today announced the closing of the acquisition of the assets of the OcuHub business unit from AOAExcel, Inc., the for-profit subsidiary of the American Optometric Association ("AOA". TearLab Corporation Reports 2013 Financial Results
GlobeNewswire - Thu Mar 13, 3:02PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
today reported its consolidated financial results for the quarter and the year ended December 31, 2013. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles. TearLab to Participate in March Investor Conferences
GlobeNewswire - Tue Mar 04, 8:00AM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
announced today that the Company will participate in three investor conferences in March. TearLab Corporation to Release Q4 and Full Year 2013 Financial Results on March 13, 2014
GlobeNewswire - Mon Mar 03, 3:30PM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q4 2013 and full year 2013 financial results after market closes on Thursday, March 13, 2014. TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. This call will be held at 4:30pm Eastern at 877-303-1593.
TearLab to Acquire AOA's OcuHub Technology Platform
GlobeNewswire - Tue Feb 18, 7:02AM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
today announced it has signed a non-binding term sheet to purchase the assets of the OcuHub business unit from AOAExcel, Inc., the for-profit subsidiary of the American Optometric Association ("AOA". TearLab Announces Preliminary Fourth Quarter 2013 Revenue and Issues 2014 Revenue Guidance
GlobeNewswire - Mon Feb 03, 7:00AM CST
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
today announced total revenue for the fourth quarter of 2013 is expected to be approximately $4.5 million, bringing expected full year 2013 revenues to approximately $14.7 million. These figures are preliminary and unaudited and final revenues may differ. The Company currently expects to report final 2013 financial results on March 13, 2014. TearLab Reports on Launch of a New 1,000 Patient Multi-Center DED Prevalence Study in the UK
GlobeNewswire - Tue Dec 17, 7:00AM CST
In collaboration with the United Kingdom's National Health Service (NHS), four ophthalmologists are beginning a large 1,000 patient multi-center study to assess the overall prevalence of Dry Eye Disease ("DED"
. TearLab to Participate in Craig-Hallum's 4th Annual Alpha Select Conference
GlobeNewswire - Thu Sep 19, 8:20AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
announced today that its Chief Executive Officer, Elias Vamvakas, will present an update on the Company's business at the 4th Annual Craig-Hallum Alpha Select Conference on Thursday, September 26, 2013 at 8:35 a.m. Eastern Time in New York City. TearLab to Participate in the Canaccord Genuity 33rd Annual Growth Conference
GlobeNewswire - Wed Aug 07, 7:55AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company"
announced today that its Chief Executive Officer, Elias Vamvakas, will present an update on the Company's business at the Canaccord Genuity 33rd Annual Growth Conference on Wednesday, August 14, 2013 at 11:00 a.m. Eastern Time. The conference will be held at the Intercontinental Boston Hotel in Boston, MA. TearLab Corporation to Release Q2 2013 Financial Results on August 13, 2013
GlobeNewswire - Wed Jul 31, 7:00PM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q2 2013 financial results after market closes on Tuesday, August 13, 2013.
TearLab Announces Exercise of Underwriters' Over-Allotment Option and Closing of $40.4 Million Public Offering of Common Stock
GlobeNewswire - Tue Jul 30, 10:40AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that it has closed the previously announced underwritten public offering of 2,990,000 shares of its common stock at a price to the public of $13.50 per share for gross proceeds of approximately $40.4 million. The shares include 390,000 shares of common stock sold pursuant to the over-allotment option granted by TearLab to the underwriters, which option was exercised in full. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by TearLab, will be approximately $37.5 million.
TearLab Corporation Prices $35.1 Million Public Offering of Common Stock
GlobeNewswire - Thu Jul 25, 8:00AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced the pricing of an underwritten public offering of 2,600,000 shares of its common stock at a price to the public of $13.50 per share for gross proceeds of $35.1 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by TearLab, will be approximately $32.6 million. TearLab has also granted the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover overallotments.
TearLab Corporation Announces Proposed Public Offering of Common Stock and Preliminary Second Quarter Financial and Operational Results
GlobeNewswire - Mon Jul 22, 6:00AM CDT
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or "the Company"
announced today its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company currently estimates the size of the offering at $30.0 million, with an estimated additional $4.5 million subject to the underwriters' over-allotment option described below. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. The proceeds of the offering will be used for commercialization of our products, research and development, working capital and other general corporate purposes. Canaccord Genuity Updates Buy Recommendation on TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) - Video Posted on InvestmentPitch.com
Thomson Reuters ONE - Mon May 27, 9:30AM CDT
Vancouver, British Columbia, May 27, 2013 - Investment firm Canaccord Genuity has updated its buy recommendation on TearLab Corporation (NASDAQ:TEAR) (TSX:TLB). Analyst Jeffrey Frelick gives the company a buy rating and raised the one-year price target from US$10.00 to US$14.00, a 46% premium to the US$9.56 price the day the report was issued.
